Oganes Akopyan
Family Medicine · Glendale, CANPI 1609098037
Payments from drug & device makers
Across 99 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$528
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- GSK$190
- Lilly USA, LLC$186
- Amgen$163
- Pfizer$156
- plus $837 from 19 others
What the payments were for
- Food & beverage$2,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $528 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $219 |
| GSK | 8 | $190 |
| Lilly USA, LLC | 8 | $186 |
| Amgen | 8 | $163 |
| Pfizer | 6 | $156 |
| Sanofi-aventis U.S. LLC | 5 | $115 |
| Novo Nordisk | 5 | $109 |
| Ardelyx, Inc. | 3 | $88 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Amarin Pharma, Inc. | 3 | $63 |
| Merck | 3 | $63 |
| Hologic Sales And Service, LLC | 2 | $51 |
| Stryker | 1 | $38 |
| Exact Sciences | 1 | $31 |
| Krystal Biotech Inc | 1 | $27 |
| Phadia US Inc. | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $13 |
How this compares
$2,278 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 118 | $68,647 |
| LinzessLinaclotide | 40 | $20,660 |
| OzempicSemaglutide | 21 | $19,573 |
| JardianceEmpagliflozin | 31 | $18,170 |
| TrulicityDulaglutide | 16 | $14,623 |
| VascepaIcosapent Ethyl | 50 | $14,051 |
| Icosapent Ethyl | 57 | $9,940 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $9,287 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $8,270 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,566 |
| Dexlansoprazole DrDexlansoprazole | 30 | $4,539 |
| Diclofenac Sodium | 51 | $1,696 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,282 |
| Omega-3 Acid Ethyl Esters | 33 | $1,169 |
| Atorvastatin Calcium | 442 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $63 | $76,917134 claims |
| AbbVieLinzess | $528 | $20,66040 claims |
| Novo NordiskOzempic | $109 | $19,57321 claims |
| Lilly USA, LLCTrulicity | $186 | $14,62316 claims |
| GSKAnoro Ellipta | $190 | $5,56612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Glendale
- Esther YoonGlendale$5.8M
- David HanGlendale$2.3M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.